Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mucinex NDA pipeline

This article was originally published in The Tan Sheet

Executive Summary

Adams Labs will submit NDAs in 2003 for respiratory products combining guaifenesin with pseudoephedrine and guaifenesin with dextromethorphan, firm says Jan. 21. Adams receives same-day FDA approval for 1,200 mg guaifenesin tablets (NDA 21-282/S-001), which will join 600 mg dose in March with similar behind-the-counter sales strategy. Mucinex 1,200 mg offers convenient dosing regimen of one tablet twice a day and is indicated to "help loosen phlegm" and "make coughs more productive." A 20-count bottle will retail for roughly $15, Adams says. Like Mucinex 600 mg, the higher dose will be promoted to physicians, pharmacists (1"The Tan Sheet" July 22, 2002, p. 3)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS095059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel